Hypogonadism is a frequent condition, in particular during adult age. Whereas no doubts exist on the opportunity of treating patients with hypogonadism deriving from definite conditions affecting the hypothalamic-pituitary-testicular axis, more concerns are present for treatment of men with age-related testosterone (T) decline, the so-called late onset hypogonadism (LOH). Several options are available for treating hypogonadism and the choice should be done according to rationale indications and expected outcomes, taking also into account the advantages and disadvantages associated with each molecule and preparation. Although GnRH and gonadotropins are the cornerstone of therapy in secondary hypogonadism (sHG) men requiring fertility, few data are present on their use in LOH. Testosterone replacement therapy (TRT) is the most studied therapy in this particular and controversial condition. Randomized clinical trials (RCTs) on TRT are few and short lasting. However, there is substantial consistence on the efficacy of TRT in improving sexual function, increasing lean mass and decreasing fat mass. The results are more controversial on the effectiveness of TRT in improving glycolipid profile and mood. Concerning bone mineral density, the evidence is scarce and those concerning fractures are non-existing. An intense debate is ongoing on the putative risk of cardiovascular (CV) events associated with TRT. Pending results from RCTs specifically designed for assessing this outcome, available evidence reassures on CV safety of TRT but caution should be used in older and frail men.

Treatment of Hypogonadism / Rastrelli, Giulia; Maggi, Mario. - STAMPA. - (2017), pp. 1-34. [10.1007/978-3-319-29456-8_32-1]

Treatment of Hypogonadism

Rastrelli, Giulia
Writing – Original Draft Preparation
;
Maggi, Mario
Writing – Review & Editing
2017

Abstract

Hypogonadism is a frequent condition, in particular during adult age. Whereas no doubts exist on the opportunity of treating patients with hypogonadism deriving from definite conditions affecting the hypothalamic-pituitary-testicular axis, more concerns are present for treatment of men with age-related testosterone (T) decline, the so-called late onset hypogonadism (LOH). Several options are available for treating hypogonadism and the choice should be done according to rationale indications and expected outcomes, taking also into account the advantages and disadvantages associated with each molecule and preparation. Although GnRH and gonadotropins are the cornerstone of therapy in secondary hypogonadism (sHG) men requiring fertility, few data are present on their use in LOH. Testosterone replacement therapy (TRT) is the most studied therapy in this particular and controversial condition. Randomized clinical trials (RCTs) on TRT are few and short lasting. However, there is substantial consistence on the efficacy of TRT in improving sexual function, increasing lean mass and decreasing fat mass. The results are more controversial on the effectiveness of TRT in improving glycolipid profile and mood. Concerning bone mineral density, the evidence is scarce and those concerning fractures are non-existing. An intense debate is ongoing on the putative risk of cardiovascular (CV) events associated with TRT. Pending results from RCTs specifically designed for assessing this outcome, available evidence reassures on CV safety of TRT but caution should be used in older and frail men.
978-3-319-29456-8
978-3-319-29456-8
Endocrinology of the Testis and Male Reproduction, Endocrinology
1
34
Rastrelli, Giulia; Maggi, Mario
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1120631
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact